Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,205
Out of 5,238 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $33.46 | +25.52% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $168.78 | +122.18% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $60.00 | +91.67% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $62.56 | +47.06% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $19.08 | -37.11% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $14.77 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $71.77 | +25.40% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $207.45 | +30.15% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $133.52 | -49.07% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $24.80 | +81.45% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $133.06 | +106.67% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $26.69 | +38.63% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $60.61 | -1.01% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $53.93 | -35.10% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $154.16 | -47.46% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $33.46
Upside: +25.52%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $168.78
Upside: +122.18%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $60.00
Upside: +91.67%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $62.56
Upside: +47.06%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $19.08
Upside: -37.11%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $14.77
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $71.77
Upside: +25.40%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $207.45
Upside: +30.15%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $133.52
Upside: -49.07%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $24.80
Upside: +81.45%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $133.06
Upside: +106.67%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $26.69
Upside: +38.63%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $60.61
Upside: -1.01%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $53.93
Upside: -35.10%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $154.16
Upside: -47.46%